What's Happening?
A significant life sciences campus located in Raritan Borough, Somerset County, has been put on the market for sale by JLL. The property, situated at 1001 Route 202, spans 66.08 acres and comprises 14 buildings totaling 596,183 square feet. This includes
320,183 square feet of lab and office space, 186,000 square feet dedicated to pharmaceutical manufacturing, and 63,000 square feet of warehouse space. The offering includes a short-term leaseback arrangement upon closing, with the seller aiming to finalize the sale in 2026 and execute a leaseback through December 31, 2027. This strategy is designed to provide immediate income for the investor while allowing ample time for site plan approvals and entitlements. The site, formerly home to Ortho-Clinical Diagnostics Inc., a Johnson & Johnson division, has undergone $9.4 million in capital improvements since 2021 and features a 1.7-megawatt owned solar array and robust power infrastructure.
Why It's Important?
This sale represents a notable opportunity within the U.S. life sciences real estate sector, particularly in New Jersey, a hub for pharmaceutical and biotechnology industries. The inclusion of a short-term leaseback provides a unique investment structure, offering immediate cash flow to the buyer while mitigating vacancy risks during the initial ownership period. The property's OM-3 or limited industrial district zoning allows for diverse repositioning or redevelopment options, including lab and life science facilities, GMP manufacturing, and warehousing, which are critical for the growing healthcare and pharmaceutical sectors. The substantial capital improvements and existing infrastructure, such as the solar array and power capabilities, enhance its appeal, potentially attracting investors looking for ready-to-use or easily adaptable facilities. The high average household income and educated populace in the surrounding area also suggest a strong talent pool, which is crucial for life sciences operations.
What's Next?
The JLL team, including Jose Cruz, Dan Loughlin, Jeremy Neuer, Michael Kavaler, Nicholas Stefans, and Jason Lundy, will continue marketing the property to potential investors. Ryan Carroll and Jason Benson from JLL are available to advise on financing and leasing, respectively. The seller's plan to close the sale in 2026 and execute a leaseback through December 31, 2027, indicates a structured transition period. Prospective buyers will likely evaluate the site's potential for redevelopment or repositioning, considering the existing zoning that permits various industrial and life science uses. The focus will be on securing a buyer who can maximize the site's value through strategic investments and leveraging its established infrastructure and location within a key life sciences corridor.
Beyond the Headlines
The sale of this Somerset County campus underscores a broader trend in the U.S. real estate market where specialized properties, particularly in the life sciences sector, are highly sought after. The strategic decision to include a leaseback clause reflects a sophisticated approach to asset disposition, balancing the seller's need for a smooth exit with the buyer's desire for immediate returns and future flexibility. This transaction could set a precedent for similar deals in the market, influencing how large-scale industrial and research properties are valued and transacted. Furthermore, the property's history as a Johnson & Johnson division and its subsequent acquisitions highlight the dynamic nature of corporate real estate portfolios and the continuous evolution of the life sciences industry's footprint in the U.S.
